THE high use of metformin monotherapy reflects its place in guidelines as first line therapy, says the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee.
The data also reveals that the use of flozins and gliptins is increasing but "overall use of diabetes medicines appears generally within PBS restrictions".
DUSC also noted that 22 major submissions had been received for the Mar 2017 meeting of PBAC.
Many other observations were summarised in the report.
Visit pbs.gov.au for the report.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Mar 17
